FATE — FATE THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1434316 ·
Last close
$2.06
Market Cap
$240.11M
52W High
$2.88
52W Low
$1.04
ADV30
4,612,667
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,299,000 | — | -33,000,000 | -31,213,000 | 284,916,000 | 39,570,000 | 105,209,000 |
| Dec 2025 | 1,369,000 | — | -34,721,000 | -32,374,000 | 318,937,000 | 46,628,000 | 111,753,000 |
| Sep 2025 | 1,741,000 | — | -34,735,000 | -32,250,000 | 343,671,000 | 40,622,000 | 109,605,000 |
| Jun 2025 | 1,907,000 | — | -36,968,000 | -34,070,000 | 371,632,000 | 41,249,000 | 110,268,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-103,097,000
Investing CF
$92,080,000
Financing CF
$5,490,000
CapEx
$-4,996,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,565,522,000
Inventory
—
Receivables
$704,000
ST Investments
$135,252,000
EBIT TTM
$-139,424,000
Pretax Income TTM
$-129,907,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,316,000
EBITDA
$-125,838,000
Free Cash Flow
$-50,068,500
Enterprise Value
$142,077,920
Total Cash
$174,822,000
Total Debt
$76,785,000
Shares Out
116,559,186
Trailing EPS
$-1.09
Book Value
$1.55
ROE
-55.5%
ROA
-25.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,646,000 | -147,704,000 | -136,315,000 | 318,937,000 | 111,753,000 | — | -106,084,000 |
| Dec 2024 | 13,631,000 | -195,539,000 | -186,262,000 | 440,694,000 | 121,968,000 | — | -122,874,000 |
| Dec 2023 | 63,533,000 | -190,511,000 | -160,928,000 | 506,217,000 | 137,800,000 | — | -132,263,000 |
| Dec 2022 | 96,300,000 | -308,386,000 | -281,721,000 | 705,561,000 | 221,622,000 | — | -248,208,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.92
Max Pain — expiry 2026-11-20
max pain strike: $2.00 · spot: $2.01 · call oi: 2,619 · put oi: 609
Expected Move to 2026-11-20:
±$1.23
(60.95%) —
implied range
$0.78 –
$3.23
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVXL | ANAVEX LIFE SCIENCES CORP. | $231.68M | $2.50 | — |
| IVVD | Invivyd, Inc. | $226.85M | $0.77 | — |
| SABS | SAB Biotherapeutics, Inc. | $254.63M | $3.33 | — |
| CLLS | Cellectis S.A. | $224.37M | $3.09 | — |
| IKT | Inhibikase Therapeutics, Inc. | $220.49M | $1.67 | — |
News headlines (Yahoo Finance, 1h cache)
Fate Therapeutics Appoints Laura Hamill to Board of Directors
2026-06-15 12:30 · Yahoo
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT
2026-06-10 18:22 · Yahoo
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
2026-06-04 12:30 · Yahoo
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 20:05 · Yahoo
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
2026-06-01 12:30 · Yahoo
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?
2026-05-30 14:45 · Yahoo
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-05-21 12:30 · Yahoo
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
2026-05-13 13:40 · Yahoo
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
2026-05-13 12:30 · Yahoo
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
2026-05-11 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.